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Figure legends
Figure 1. Illustration of the TEAMS CDSS tool used by nurse for data entry and guideline based
assessments during telemedicine visits (left), including built-in patient educational modules from
the Let's Talk About Asthma series for smartphone (right)
Online supplemental materials legend
Figure E2. Sample progress note auto-generated by the TEAMS CDSS tool
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Abstract
Background: Technology-based interventions that can function within real-world practice and
improve outcomes without increasing provider burden are needed, yet few successfully cross the
research-to-practice divide. This paper describes the process of developing a clinically-integrated
smartphone-telemedicine program for adults with asthma and results from proof-of-concept
testing.
Methods: To ensure integration with practice, we used a contextually-grounded intervention
development approach and May's implementation theory to design the intervention, with
emphasis on systems capabilities and stakeholder needs. The intervention incorporated symptom
monitoring by smart phone, smartphone telemedicine visits and self-management training with a
nurse, and clinical decision support software, which provided automated calculations of asthma
severity, control, and step-wise therapy. Seven adults (aged 18-40) engaged in a 3-month betatest. Asthma outcomes (control, quality of life, FEV1) and healthcare utilization patterns were
measured at baseline and end-of-study.
Results: Each participant received an average of 4 telemedicine visits with 94% patient
satisfaction. All participants had uncontrolled asthma at baseline; by end-of-study 5/7 classified
as well controlled. Mean asthma control improved 1.55 points (CI=0.59-2.51); quality of life
improved 1.91 points CI=0.50-3.31), and FEV1 percent predicted increased 14.86% (CI=-3.0932.80) with effect sizes of d=1.16, 1.09, and 0.96, respectively. Preventive healthcare utilization
increased significantly (1.86 visits/year vs. 0.28/year prior, CI 0.67-2.47) as did prescriptions for
controller medications (9.29 refills/year vs. 1.57 refills/year, CI 4.85-10.58).
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Conclusion: Smartphone telemedicine may be an effective means to improve outcomes and
deliver asthma care remotely. However, careful attention to systems capabilities and stakeholder
acceptability is needed to ensure successful integration with practice.

Clinical Trials registration #: NCT03648203
Funding: Research reported in this publication was supported by Sigma Theta Tau, Epsilon Xi.
The content is solely the responsibility of the authors and does not necessarily represent the
official views of the sponsors.
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Introduction
Asthma remains one of the most common chronic health conditions, affecting 8.2% of
adults, of which approximately 63% have persistent symptoms.1, 2 Typically, correct use of
controller medication and effective self-management can alleviate symptoms, prevent
exacerbations, and reduce risk of long-term lung damage.3 Yet while morbidity and mortality
due to asthma are preventable, nearly 62% of adults with asthma remain uncontrolled, and
implementation of potentially effective new interventions within real-world contexts has been
limited.4
There is no doubt that careful assessment, close follow-up, medication reminders, and
self-management training all improve adherence and outcomes.4 However, these approaches
require personnel and time resources that may not exist within over-burdened healthcare
systems. With the growing shortage of primary care providers (PCP) and the increasing
complexity of clinical care, it is unlikely that PCPs can carve out additional time to focus on
asthma management.5 For this reason, interventions that can function effectively within existing
systems’ constraints and improve patient outcomes without increasing provider burden are
urgently needed.
There is growing evidence that use of e-health technology (e.g. smartphones, electronic
medical record, and computer decision-support software "CDSS") can address common asthma
management issues.6, 7 However, most technology-based interventions do not integrate with the
electronic medical record (EMR), and are thus not currently clinically sustainable. While
researchers may be optimistic about the ability to integrate ex post facto, few tech-based
interventions cross the research to practice divide, typically due to unforeseen systems
implementation issues or incompatibility with existing clinical workflow.
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Thus, in designing a new technology-based intervention for asthma management, we
adopted a contextually grounded intervention development approach that allowed for
consideration of implementation issues during the development process 8. Specifically, we
sought to develop a smartphone-based telemedicine program that could address common asthma
management problems (e.g. patient non-adherence,9-11 inaccurate symptom reporting,12, 13 poor
self-management,14, 15 access to care,16-18 and provider nonadherence to asthma guidelines19-21)
and integrate with the EMR and existing clinical practice. The goal in developing the
intervention was to increase the accuracy, effectiveness, and convenience of care for patients,
while avoiding increased clinician burden and promoting adherence to guidelines.22-26 In this
manuscript, we describe the process of contextually grounded intervention development, the
resulting technology, and proof of concept testing in a small, real-world sample of adult patients
in a large urban medical center. We hypothesized that the intervention would show preliminary
evidence of feasibility and acceptability and potential to improve asthma outcomes in younger
adults with asthma.

TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)
Methods
Intervention Development
As shown in Table 1, we navigated an extensive two-year planning and development
process aligning with May's implementation theory,27 including identifying problems and
solutions, target environments, system capabilities, key stakeholders, practice policies, and
credentialing processes. Development required establishing key relationships; assembling a
representative team, creating and testing the technology, obtaining approval to launch, and proofof-concept testing with patients in the clinical setting.
Technology Enabled Asthma Management System (TEAMS) is a fully integrated EMRbased intervention designed for use in primary care. Based on the process described above, three
technological components were selected to augment routine asthma care: (a) remote smartphone
symptom monitoring, (b) synchronous smartphone telemedicine follow-up and self-management
training with a nurse, and (c) computer-guided EMR assessments using built-in clinical decisionsupport software (CDSS). Patients recorded home-entered symptoms using their smartphones
and a patient portal app (Mychart; Epic Systems Corporation, Wisconsin USA), which uploaded
symptom data directly to the Epic EMR. One nurse (JRM) conducted telemedicine visits using
Zoom's HIPAA-compliant secure video-conferencing platform (Zoom Inc. California USA).
The nurse reviewed home-entered symptoms and entered a detailed asthma assessment into the
TEAMS CDSS flowsheet (see Figure 1), which is a complex clinical documentation and
decision-making tool embedded in the EMR. Guideline-based algorithms in the CDSS tool
instantaneously calculated asthma severity, control, and provided a comparison of recommended
versus prescribed step-wise therapy. The CDSS tool was designed to improve assessment
accuracy, guide step-wise medication management,4 inform providers, and help patients achieve
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better asthma control. Results of the analyses were shared with the participant and evidencebased self-management training was provided using the free online resource Let's Talk About
Asthma! e-series for smartphone developed in our prior work.28, 29 A detailed progress note
autogenerated by the CDSS tool (see Figure E1, online supplement) was filed in the EMR for
each telemedicine visit. Per protocol, an EMR InBasket message with a visit summary was sent
to the PCP team if the patient had uncontrolled asthma and needed medication adjustments or
office follow-up, with a back-up phone call for urgent issues. To ensure safety and monitor for
correct functioning of EMR algorithms, all telemedicine visits in this phase were conducted by
an advanced practice nurse with IT training (JRM), and each calculated output was verified for
accuracy.
CDSS calculations used National Asthma Education Prevention Program guidelines4 but
are adaptable to other guidelines. Program components are likely compatible with other EMRs.
Approach (Proof-of-concept testing)
This study was approved by the University of Rochester Internal Review Board
(RSRB67900). A mixed methods approach was used. The quantitative portion consisted of a
single-arm pilot study with pre-post and longitudinal collection of outcomes over 3 months
(asthma control, quality-of-life, Forced Expiratory Volume (FEV1), ED visits, hospitalizations,
feasibility/acceptability surveys). The qualitative portion used descriptive methodology and
open-ended interviews to capture patients’ experiences and perceptions of TEAMS, to explore
acceptability and perceived impact. Staggered enrollment was used to account for seasonal
variation in symptoms.
Setting and sample
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Participants were randomly selected from clinic rosters in an urban safety-net residentrun primary care clinic in Western NY. Eligibility criteria were: ages 18-40, with any diagnosis
of current asthma, English speaking, and having a smartphone. Age range was restricted to
younger adults (18-40 years) on the basis of smartphone prevalence and technology uptake.
Patients with confounding comorbidities (e.g. heart failure COPD, Cystic fibrosis) and pregnant
patients were excluded. Patients with psychiatric diagnoses were not excluded. Ten patients,
randomly selected from clinic rosters, were screened; all had smartphones. One was ineligible
on the basis of heart failure and two who were eligible could not be re-contacted after screening.
The remaining seven consented and completed the beta-test (3-month duration).
Intervention delivery
Written informed consent and all study procedures were performed by a trained nonmedical research assistant in patients’ homes due to high office-visit no-show rates. Technology
set up and training occurred at the baseline visit. Participants were asked to record symptoms,
medication use, and Peak Expiratory Flow (PEF) using a Microlife30 digital peak flow meter
(Microlife, USA) via smartphone, daily, for 3 months. A nurse (JRM) initiated follow up
smartphone telemedicine visits with patients every 2-weeks until asthma control was achieved,
as calculated by the TEAMS CDSS tool. All visits were scheduled by text messaging and text
message reminders were sent the day prior to or the day of appointment. Following each visit, if
the CDSS tool indicated that the patient's asthma was uncontrolled, a brief synopsis was sent to
PCP via EMR InBasket messaging with urgent messages also conveyed via phone call. The
PCP then initiated medication adjustments via e-prescribing, if warranted, and determined
medically appropriate follow-up. The TEAMS nurse then helped to coordinate care and ensure
follow up. Once the patient achieved good asthma control, follow up frequency decreased to
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once a month. There was no minimum requirement for participation in self-monitoring or
telemedicine visits and patients participated in each activity as often as they were motivated to.
Intervention dose for each participant was tracked and correlated with outcomes.
Outcome Measures
Feasibility was measured by: (a) frequency of participation in symptom monitoring, (b)
number of visits needed to achieve/maintain asthma control, (c) duration of visits, and (d) no
show and reschedule rates. Similar to clinical practice, length of visit was driven by the time it
took to complete the asthma assessment, teach participants specific self-management skills, and
relay follow up documentation to PCP/clinic. Thresholds for minimum or maximum
intervention dose were not predefined, as the goal was not to deliver a standard intervention
dose, but to assess dose needed to achieve good control or dose tolerated (e.g. frequency of
voluntary participation), and relationship between intervention dose, asthma control, and quality
of life.
Efficacy. Primary outcomes (asthma control, quality of life, and FEV1 percent predicted)
were collected at baseline and end of study. Asthma control and quality of life were measured
using the Asthma Control Questionnaire (ACQ)31 and Asthma Quality of Life Questionnaire
(AQLQ), respectively.32
ACQ. The ACQ is a well-established 7-item questionnaire with a score range of 0-6
(lower scores represent better control). A score of ≦0.75 has a positive predictive value of 0.85
for controlled asthma, and a score of ≧ 1.5 has a positive predictive value of 0.88 for
uncontrolled asthma.31 Minimum important difference is a change score of 0.5.33
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AQLQ. The AQLQ measures physical and emotional impact of disease with high testretest reliability (>0.90).32 Averaged total scale and subscale scores range from 1-7, with higher
scores representing better quality of life. Minimum important difference is 0.5 per domain and
overall quality of life.34
FEV1 was measured using Microlife digital PFMs.30 FEV1 percent predicted was
calculated using NHANES III criteria.35, 36 Number of prescriptions written by providers for
asthma medications were obtained through EMR review for the year pre and post intervention.
Actual refills by patients could not be accurately determined due to external pharmacies data
storage procedures.
Acceptability was assessed at the end of the study through 1:1 interview and the Usability
Satisfaction and Ease of Use Questionnaire (USE-Q). The USE-Q37 is a validated 21-item
instrument with a 7-point Likert scale format (1=strongly disagree to 7=strongly agree). Higher
scores represent more positive perceptions, with 7 being the most positive possible score and 1
representing the most negative possible score. Minimum acceptability thresholds were a score
≥5=somewhat agree on at least 70% of USE-Q items. Exit interviews were conducted to
qualitatively explore acceptability.
Demographics were collected via survey and the EMR.
Data analysis
Descriptive statistics were computed for demographics, feasibility, and USE-Q data.
Paired t-tests were used to compare baseline and end of study scores for ACQ, AQLQ, and FEV1
percent predicted, and effect sizes (Cohen's d) were calculated. Unadjusted bivariate correlation
was used to explore associations between asthma control and quality of life (ACQ, AQLQ) and
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intervention dose (frequency of self-monitoring and telemedicine visits). Audio-recorded
interviews were transcribed and qualitative content analysis techniques38 were used to explore
participants’ perceptions of the program.
Results
Baseline asthma and demographic data are presented in Table 2.
Feasibility. Of 42 scheduled telemedicine visits, 7 were no-shows (16%; involving 4/7
patients), 7 rescheduled (16%; involving 4/7 patients), and 28 were conducted as expected
(68%). Participants averaged 4 telemedicine visits (range 3-5), for a grand mean of 114 minutes
spent with the asthma telemedicine nurse (range 88-160 minutes; SD 25.07; average 61 minutes
self-management training and 53 minutes nursing-assessment per participant). Participants
logged symptoms remotely an average of 32 days over 3 months (range 15 to 64; SD 15.56).
Participants were asked to set a daily reminder on their smartphone; no external reminders were
provided for self-monitoring. Average telemedicine visit duration was 29 minutes (range 20-45
minutes), and the majority of visits (17/28; 61%) were delivered after 5pm or on weekends to
accommodate participants’ work schedules.
Efficacy. At baseline, all participants had uncontrolled asthma. At 3-months, 6/7
participants had marked reduction in symptoms with 5/7 classifying as well-controlled 39. Effect
sizes were large for improvements in control, quality of life, and FEV1 percent predicted (d=0.96
to 1.16). Table 3 shows pre-post scores for asthma outcomes with effect sizes and confidence
intervals. On average, asthma control improved 1.55 points—more than 3 times the clinical
MID. Significant improvements were seen in morning symptoms, night time wakening, activity
limitations and shortness of breath, with greatest effects on reductions in wheezing (d=1.48).
Quality of life improved an average of 1.91 points, nearly 4 times the minimum important
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difference (MID). Improvements were evenly distributed across all domains (symptoms, activity
limitations, emotional functioning, and environmental stimuli. There was also an average
increase of approximately 15% in FEV1 percent predicted.
Table 4 shows individual peak flow graphs (extracted from the EMR) with a noticeable
upward trend in PEF for most participants. Graphs for the first two participants showed
downward or neutral trends. Association between number of days participants performed home
self-monitoring, length of visit, and improvement in asthma control was moderate (r= 0.67 and
p=0.10).
An average of 2 (range 1-4; SD 1.29) InBasket messages per participant were sent by the
TEAMS nurse to the participants' PCP (n=4) over 3 months, to coordinate follow-up care and
medication adjustments, with 100% PCP response. As seen in Table 3, there were significant
and clinically meaningful increases in use of preventive health services and written prescriptions
for controller medications, and a corresponding decrease in prescriptions for oral corticosteroids
in the year following intervention.
Acceptability. As shown in Table 5, acceptability and satisfaction was high (93.9%). At
exit interviews, six of seven participants reported that the intervention “changed my life” and
enabled them to take control of their asthma for the first time. Qualitative data on the perceived
impact of the intervention are presented in Table 4.
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Discussion
Data from this proof-of-concept study suggest that use of an integrated smartphone and
EMR/practice-based intervention might be an effective means to supplement primary asthma
care and improve outcomes. The underlying importance of this approach lies in the ability to
reduce barriers to accessing primary care.18 Telemedicine is inherently more flexible than office
care, and does not require that patients travel to a given location. Extending telemedicine into
patients' homes via ubiquitously available smartphones could make communities the front-line
for primary care. Because of ability to supersede geographic boundaries, smartphone technology
could increase clinical reach, and may thus be the key to delivering care to underserved
populations locally and globally.
Prior studies have demonstrated that use of remote monitoring, self-management training,
telemedicine, smartphones, and CDSS tools, individually, can improve outcomes.40-42 To our
knowledge, however, this is the first intervention to combine these components into a single
technological package that effectively integrates with real-world medical practice and the live
EMR.
In contrast to studies that have sought to isolate and quantify the impact of individual
factors,43, 44 this study adopted a broad-spectrum approach with simultaneous intervention across
multiple patient, provider and systems levels, as we theorized that the impact of a multifaceted
program would likely be different from the impact of individual components in isolation 45, 46.
The marked improvement in outcomes, as evidenced by large effect sizes on key outcomes
(d=0.96 to 2.62), supports this holistic approach. On average, participants achieved a 15%
increase in FEV1, crossing the critical clinical threshold of >80%.39 Additionally, improvements
in asthma control and quality of life that were 3-4 times the minimum important difference.31, 34
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Patients’ perceptions of acceptability and feasibility were high, and while participants only
recorded symptoms only 33% of the time on average, greater engagement was associated with
improved asthma control. Lastly, the significant increase in written prescriptions for controller
medications and in-office PCP follow up suggest that the intervention can promote provider
adherence to guideline-based care, in addition to improving patient specific outcomes.20, 47
From a systems standpoint, clinical feasibility and affordability has yet to be determined.
In this small sample, no-show and reschedule rates for telemedicine visits was only slightly
better than office visit attendance rates (66%), with 68% of telemedicine visits conducted as
expected 48. Further research is needed to determine cost-effectiveness and institutional
capability to run a program that operates heavily during evening and weekend hours.
Furthermore, given that participants required an average of 114 minutes of individualized asthma
education with a nurse to achieve and maintain control, the TEAMS approach is likely to require
greater upfront investment by insurers and the medical community to achieve long-term societal
gain. Yet, it is abundantly clear that current approaches to "feasible and affordable care" are not
effective, as the majority of patients with asthma remain chronically uncontrolled. Thus, it may
be necessary to stretch healthcare boundaries and explore ways to make effective care affordable,
rather than perpetuating systems that are affordable but largely ineffective. In short, moving
towards an aggressively proactive rather than reactive approaches to asthma management is
essential to changing long-term health trajectories.46
Limitations. This proof-of-concept study used a small sample. Patients were
predominantly younger, minority, lower SES, lower health-literacy, with moderate/severe
uncontrolled asthma, and the intervention was delivered by a single nurse. Further research in a
larger and more representative population, with diverse interventionists is needed to replicate
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findings, evaluate who the intervention is most effective for, and determine if all intervention
components are necessary to achieve similar outcomes.
Despite limitations, we believe these data are compelling, and the processes delineated
herein will be useful to those seeking to develop and implement technology-based clinical
interventions. Several important lessons were learned: First, the technology took nearly two
years to conceptualize, build, and integrate into practice, which was longer than anticipated. The
majority of this time was spent navigating systems level barriers, gaining access to EMR
build/programming environments, and getting healthcare provider buy-in. It is well-known that
many potentially effective interventions are never integrated into clinical practice or the EMR.
Our experience suggests that this may be partly due to failure to account for powerful real-world
constraints. As seen throughout the development process (Table 1), we found that wherever the
intervention disrupted existing practice (even by small amounts), it was met with resistance.
Conversely, by avoiding workflow changes and carefully incorporating stakeholder feedback, we
were able to minimize resistance and increase support for the intervention. It is also worth
noting that even with using a contextually-grounded intervention development approach, where
the intervention was crafted to the clinical context, there was still need for additional on-theground customization to account for unanticipated barriers (e.g. trouble engaging patients in
office settings; preference of clinic providers to delegate use of the CDSS tool to nursing care).
Thus, the final intervention that was implemented was noticeably different than originally
conceptualized. Use of focus groups, interviews, community engagement studios, and close
collaboration with key stakeholders are important precursors to developing a clinically
sustainable intervention.27 Additionally, careful negotiation of institutional practices for new
EMR build and IT and administrative support will be essential, as there are substantial barriers to
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new technology within the EMR due to potential for far-reaching negative systems impact.
Based on these experiences, we conclude that use of advanced EMR, CDSS, and smartphone
technology has strong potential to improve asthma care, but premature intervention development
without sufficient groundwork could be detrimental to long-term success.
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TABLE 1. Process of contextually grounded intervention development
Key components of process
PLANNING STAGE
Problems
• Identify target population and specific problems
and potential • Assess population capabilities, barriers, facilitators
solutions
• Define approaches that might work for problem and
population using prior evidence and theory
Target
environment

• Identify environments with access to target population
• Assess clinical capability, preparedness, and willingness
to adopt a new intervention
• Identify current clinical structure (physical resources,
ways of operating, workflow and scheduling patterns)
• Develop awareness of general and specific barriers
(staff, provider, or clinic resource limitations)
• Determine approaches that might work for clinical
context, patient population, and identified problems

System
capabilities

• Identify system capabilities (technological,
programmatic, IT resources, supports/barriers)
• Identify implementation barriers (e.g. moratorium on new
EMR build, anticipated build time and available build
resources (personnel and systems access issues),
willingness to support novel research-based build)

Key
stakeholders

• Define potential impact of intervention (development and
implementation) on patient, staff, and systems revenue
or resources to identify stakeholders
• Recognize and respect needs and perspectives of
stakeholders who may impact intervention uptake (e.g.
patient, community, support staff, nursing, provider,
administrative, IT and data security, research, reporting,
insurers)

Examples
Population: Adults at risk for uncontrolled asthma (urban, minority,
underserved, low SES, low health literacy)
Problems: Poor access to care; No show and transportation issues,
Nonadherence; Poor follow-up; Poor self-management.
Opportunity: 85% adults < 40 years use smartphones regularly
Environment: Urban primary care “safety-net” practice
• Practice willing to support a tech-based asthma intervention if no negative
impact on workflow
• EMR/smartphone intervention run by nurses would be acceptable and
integrate with practice
• Modification to work flow/documentation patterns would not be supported
by providers due to increased work burden
• Limited availability of clinic appointments = delayed follow up.
• Hours of operation: Weekdays until 4:30pm, conflicts with patient needs for
afterhours and weekend care
Capabilities: Symptoms can be monitored remotely with smartphones via
patient portal to EMR interface
• Guideline-based algorithms and decision support tools in EMR can
minimize inaccuracies in clinical care
• Home-based telemedicine can improve access to care
Barriers: institutional cap on EMR build > 10 hours - requires formal review
for priority and funding; research considered lower priority than clinical
applications; limited funding available; initial plan to have clinic nurses do
telemedicine visit was found to be non-viable due to patient need for evening
and weekend visits, resulting in use of dedicated nurse interventionist
Interviews and community engagement studios to engage:
• Admin: (support for hybrid clinical/research program)
• Medical faculty (support for program w/ Resident participation)
• Residents: (support shared patient management; in-basket notification of
nursing assessments; not supportive of any workflow change/disruption;
low interest in using CDSS)
• Nursing: (gatekeeper for clinical communication pathways; open to
workflow changes if practicable, interested in maximizing scope of
practice, including use of CDSS and telemedicine follow up)
• IT department (gatekeepers for new build; review/approve build)

TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)

Practice
policies

• Identify practice policies and incorporate into design

Credentialing
and approval

• Determine what certifications may be necessary to
obtain approval or facilitate development of the
intervention (e.g. specific build or reporting certifications)
• Identify needed permissions (e.g. IRB, clinical
administration, provider/staff approvals or “buy-in”)
• Identify immediate funding sources and potential for
long-term sustainable funding

Funding
sources

• Research community (requires rigorous science/data)
• Patient and community (feedback on design, problems)
• Factor for established communication pathways, scheduling procedures,
usual follow up protocols
• Identify internal "champions" who can facilitate implementation
• (Urgent) Epic builder certification of researcher needed due to limited build
resources; EMR build had to be performed by researcher, and
administrative approval was needed at multiple levels to support this
• (Delayed) Asthma educator certification necessary for eventual insurance
billing
• Immediate: departmental and research funding
• Eventual: foundation funding → insurer reimbursement
• Current insurer policy does not reimburse for site to home telemedicine by
nursing for asthma care; however demonstration of long-term cost savings
could be used to drive policy changes

DEVELOPMENT STAGE
Establishing
relationships,
Assembling
the team

• Representative of key internal stakeholders

Developing
technology –
a systems
approach

•
•
•
•
•
•

Translate guidelines to algorithms conceptually
Draft (code), revise and test technology
Build for compatibility with existing workflow
Minimize disturbances to current clinical patterns
Seek additional feedback from key stakeholders
Modify algorithms and output based on feedback

IMPLEMENTATION STAGE
Final
• Review of the final product by stakeholders
approvals
and Launch

• Relationships: Faculty/staff, patient and community, administrative, clinical,
research, and information technology
• Team members: clinical, research, IT, administration, pharmacy,
community liaison
• Determine quantity, granularity, and specificity of data capture (categorical,
interval, or narrative)
• Determine approach to data entry (e.g. smartform, flowsheet)
• Assess if data capture approach is well situated for reporting and statistical
analyses and impact on workflow of data entry method
• Identify evidence-based guidelines and write code for CDSS
• Obtain expert review of CDSS (clinician, pharmacist, nursing)
• Test program comprehensively for analytic functioning—200 unique
clinical scenarios evaluated across multiple iterations
• Design + test CDSS auto-generated progress note, obtain clinician review
of note content and format
• Clinic permission to launch
• IRB approvals
• Beta testing with patient feedback and revision as indicated

Notes: CDSS=Clinical decision support software; EMR=Electronic medical record; IT=Information technology; SES=Socioeconomic status
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TABLE 2. Sample Baseline Characteristics (n=7)
Variable
Single (% Yes)
Low incomea (% Yes)
Employed full time (% Yes)
Public insurance (% Yes)
High School Graduate (% Yes)
Sex (% Female)
Comorbid mental illness (% Yes)b
Comorbid substance use disorder (% Yes)c
Ethnicity (%)
African American
Hispanic/Latino
Caucasian

N (%)
6 (86)
5 (71)
5 (71)
4 (57)
5 (71)
6 (86)
5 (71)
4 (57)

Any Controller Medication Use Past Month (% Yes)

3 (43)

Asthma Control (%)
Well-controlled
Not-well-controlled
Very-poorly-controlled
Asthma Severity (%)
Mild persistent
Moderate persistent
Severe persistent
Age
Years diagnosed with asthma
a

4 (57)
2 (29)
1 (14)

0
2 (29)
5 (71)
0
2 (29)
5 (71)
Mean (SD)
29.5 (5.22)
16.57 (8.33)

Low income: < 200% US Federal poverty level ($12,140 individual;
$25,100 for a family of four)49
bMental illness: bipolar, PTSD, panic disorder, anxiety/depression
cSubstance use disorders: marijuana, tobacco, alcohol
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TABLE 3. Change pre to post intervention for key clinical asthma outcomes

ACQa
Morning symptoms
Nighttime wakening
Activity limitations
Shortness of breath
Wheezing
SABA use
AQLQa
Symptom domain
Activity domain
Emotional domain
Environmental domain
FEV1%Pred

Emergency visits
Preventive office visits
Prescriptions - controller
medication
Prescriptions - SABA
Prescriptions - OCS

Baseline
Mean
(SD)
2.75
(1.27)
2.00
(0.82)
2.43
(1.71)
3.00
(1.92)
4.00
(1.52)
2.86
(1.22)
2.14
(2.04)
3.69
(1.27)
3.49
(1.60)
4.12
(1.15)
3.49
(1.59)
3.39
(1.18)
76.14%
(17.79)
Year prior
(SD)
0.28
(0.76)
0.29
(0.49)
1.57
(2.70)
4.29
(3.30)
0.43
(0.79)

End
Mean
(SD)
1.20
(1.35)
1.00
(1.00)
0.57
(1.13)
1.73
(1.90)
2.00
(2.00)
1.00
(1.29)
1.29
(1.60)
5.60
(2.13)
5.69
(2.13)
5.57
(2.21)
5.77
(1.99)
5.18
(2.29)
91.00%
(12.99)
Year post
(SD)
0
(.00)
1.86
(0.69)
9.29
(3.50)
10.57
(7.02)
0.14
(0.38)

Change
Mean
(SD)
-1.55
(1.02)
1.00
(1.00)
1.86
(1.95)
1.57
(1.27)
2.00
(1.00)
1.87
(1.34)
0.86
(1.57)
1.91
(1.53)
2.20
(1.52)
1.45
(1.44)
2.29
(2.17)
1.79
(1.86)
14.86%
(19.4)
Change
(SD)
0.28
(0.76)
1.57
(0.96)
7.71
(3.09)
6.29
(6.55)
0.28
(0.95)

Effect
(d)

P-value

CI

1.16

0.007

0.59-2.51

1.09

0.045

0.075-1.93

1.28

0.038

0.052-3.66

0.66

0.017

0.40-2.75

1.13

0.002

1.08-2.93

1.48

0.011

0.61-3.10

0.46

0.20

-0.60-2.31

1.09

0.016

0.50-3.31

1.17

0.009

0.79-3.61

0.82

0.037

0.12-2.79

1.27

0.032

0.28-4.29

0.98

0.044

0.06-3.51

0.96

0.089

-3.09-32.80

Effect
(d)
0.52

P-value

CI

0.356

-0.41-0.98

2.62

0.005

0.67-2.47

2.47

0.001

4.85-10.58

1.14

0.044

0.22-12.34

0.47

0.457

-0.59-1.17

Abbreviations. ACQ=Asthma Control Questionnaire; AQLQ=Asthma Quality of Life Questionnaire; OCS=oral
corticosteroid; SABA=short acting beta agonist
aMinimum

important difference = 0.5 per domain and total score; Large effect size (d) is considered >0.80;
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TABLE 4. Key outcomes and qualitative data by case for patients participating in TEAMS Beta test
P#
(Sex)
Race
Age

Graph of daily PEF
(extracted from EMR)

Baseline → End

Measure
ACQ

P#1
(F)
AA
40

AQLQ
FEV1%pred

P#4
(F)
AA 24

P#5
(M)
AA
29

P#6
(F)
C
24

P#7
(F)
HL
24

4

4

2.43

1.19

67

68
3

a

29

ACQ

2.14

1.29

AQLQ

3.97

5.84

85

84

FEV1%pred
# Televisits

4

# Entries

15

ACQ
P#3
(F)
HL/AA
29

Post

# Televisits
# Entries

P#2
(F)
AA
32

Pre

AQLQ
FEV1%pred

5

1.71

1.88

4.59

46

100

# Televisits

5

# Entries

64

ACQ

2.29

0.43

AQLQ

4.41

6.94

FEV1%pred

102

103

# Televisits

4

# Entries

24

ACQ

2.43

0.43

AQLQ

3.28

6.88

85

95

FEV1%pred
# Televisits

3

# Entries

24

ACQ

1.57

0.29

AQLQ

5.50

6.81

80

103

FEV1%pred
# Televisits

5

# Entries

34

ACQ

1.71

0.29

AQLQ

4.47

6.94

68

84

FEV1%pred
# Televisits

4

# Entries

36

Perceived impact of intervention
(Exit interviews)
[Before] I didn’t realize my asthma wasn’t controlled, I was
wheezing but I just thought I had a cold all the time.… I
thought I was doing pretty good even though I be out of
breath. But when I started using [the peak flow] I saw the
numbers and realized I couldn’t breathe, and that made me
want to get my lungs healthy … I’ll be honest, I didn’t used to
take my pump, but now I use it every day.
The program helped me recognize the symptoms of my
asthma…I learned if you don’t take your control medicine you
can scar your lungs—that got me to pay attention! Now that
I’m daily taking my medicine—it’s given me a whole ‘nother
breath…I thought I didn’t need it, ‘til I found out how to use it
and what it does for your body. I’m recommending this to my
family and friends—I’m spreading the word!
I realized I have the right to control my asthma. First time we
met I was crying cause all I wanted to do is breathe, but I felt
powerless. This changed my life—I’m like 100% better.
[Before] I didn’t use my inhalers cause of how I was raised.
Now I take my [control inhaler] every day. … I had a
medication that could’ve been helping me the whole time, but I
didn’t know what it was for, so I’m not gonna take it!
I used to have symptoms for hours every day, and now I
almost never do. I take my control inhaler every day and I
work out—and I couldn’t do that before. And before, if I had an
asthma attack, I wouldn’t take my inhaler, I would’ve just
called the ambulance and gone to the hospital. But [now] I
take it and it works! I have the knowledge and confidence that
I can take care of myself—This changed my life!
I’m not really having symptoms anymore, maybe once a week.
Before I was wheezing all the time, and I didn’t have any
medication, and I didn’t know what was causing it. I was
suffering. Now, I take my control medication every day. It
takes a load off a person when you get the education and you
can monitor it and control it…it changed my life dramatically. I
can breathe, and I can control it. I feel like a regular person.
It’s amazing. I recommend anyone do this.
I’m more aware and more educated about my symptoms now,
and I take my control meds every day. I used to wait out my
symptoms, thinking “it’ll go away, it’s OK.” I’m less accepting
of symptoms now because I know I’m doing damage—I was
never taught that. It’s kind of embarrassing …I’m a nurse and I
should’ve known these things. Now I can better educate my
patients and even my doctors.
(Crying) Six months ago I was scared. I was out of work for a
month because of asthma. Now I’m not scared and I know
what to do to prevent something small from getting big.
Before, I never paid for my control inhaler because it was
expensive and I didn’t know why I should get it when I could
use the cheap one. I don’t freak out now if I leave home
without my rescue inhaler because I almost never need it.

Notes. aEntries = home entered symptoms. AA=African American; ACQ=Asthma Control Questionnaire (Range 0-6; Lower scores represent better
asthma control; < 1.5 is predictive of controlled asthma); AQLQ=Asthma Quality of Life Questionnaire (Range 1-7; Higher scores represent better
quality of life); C=Caucasian; HL= Hispanic/Latino; F=Female; M=Male; P#=Participant(#); Visits=Telemedicine visits with a Nurse; Recordings=daily
home symptom and peak flow recordings via smartphone patient portal. (PEF graph images extracted from the EMR show peak flow over time and
have been flipped to display data in left to right chronological order. PEF images © 2019 Epic Systems Corporation. Used with permission.
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TABLE 5. Item scores for the Usability, Satisfaction and Ease of Use Questionnaire
Mean

Range
(1-7)

SD

7

7

0

It helps me be more productive.

6.86

6-7

0.378

It is useful.

6.71

6-7

0.488

It gives me more control over the activities in my life.

6.71

6-7

0.488

It makes the things I want to accomplish easier to get done.

6.43

4-7

1.134

It saves me time when I use it.

6.14

4-7

1.215

It does everything I would expect it to do.

6.43

4-7

1.134

It is easy to use.

6.29

5-7

0.951

It is easy to use. It is simple to use.

6.86

6-7

0.378

It is user friendly.
It requires the fewest steps possible to accomplish what I want
to do with it.

6.86

6-7

0.378

6.57

5-7

0.787

I learned to use it quickly.

6.57

5-7

0.787

I easily remember how to use it.

6.57

6-7

0.535

It is easy to learn to use it.

6.71

6-7

0.488

I am satisfied with it.

6.86

6-7

0.378

I would recommend it to a friend.

6.57

5-7

0.787

It is fun to use.

6.43

4-7

1.134

It works the way I want it to work.

6.43

4-7

1.134

It is wonderful.

6.43

5-7

0.976

I feel I need to have it.

6.14

3-7

1.574

It is pleasant to use.

6.43

4-7

1.134

Average score for survey

6.57

5.6-7

0.654

It helps me be more effective.

Notes: Likert scale range 7=Very satisfied to 1=Very dissatisfied
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Figure 1. Illustration of the TEAMS CDSS tool used by nurse for data entry and guideline based assessments during
telemedicine visits (left), including built-in patient educational modules from the Let's Talk About Asthma series for
smartphone (right) Copy right J Mammen, used with permission
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Figure E1. Sample progress note auto-generated by the TEAMS CDSS tool

Progress note
TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS)
Asthma telemedicine visit summary xx/xx/xxxx:
• Assessment: Very Poorly Controlled, likely Severe persistent asthma based on prescribed medications and
symptom pattern.
• Prescribed: SYMBICORT 160-4.5 mcg ( Budesonide-Formoterol MDI ) at a MEDIUM dose (640 mcg daily)
and is currently taking 2 puffs in the morning and 2 puffs at night (640 mcg daily - MEDIUM dose)
• Other asthma control medications: NONE (taking cetirizine for allergy)
• Recommended stepwise therapy is Step 5.
• The patient is currently taking Step 4 - Insufficient control medication

•

Plan: Schedule office visit with PCP, Follow up virtual visit in 2 weeks

DETAILED NOTE BELOW
SUBJECTIVE
XXX was seen via Zoom (telemedicine) for nursing follow up of Asthma.
The patient reports the following:
Daytime symptoms
Every day, throughout the day (maybe 2-3x day,
Well controlled <= 2 x week
mostly morning or evening). Notes recurrent chest
discomfort which resolves with albuterol
Night time wake up from asthma
Wakes three nights a week
Well controlled <= 2 x month
Use of rescue inhaler for symptoms
Using inhaler many times a day
Well controlled <= 2 x week
Activity limitations
Some limitation
Well controlled = none
Patient perceived asthma control: Very poorly controlled
Current respiratory illness: Feels fine
Any smoking in the past 6 months: Yes
Any symptoms of life-threatening asthma: No
NOTES: noticing chest discomfort all day, a pain with deep breathing, pain resolved with taking albuterol and
stays away for 3 to 4 hours then returns.
MEDICATION USE:
Prescribed: SYMBICORT 160-4.5 mcg ( Budesonide-Formoterol MDI ) and is currently taking 2 puffs in the
morning and 2 puffs at night (MEDIUM dose)—fully adherent.
Low dose is equal or less than 540mcg; High dose is greater than 1080mcg
Taking any additional long acting beta agonist or leukotriene inhibitor: NONE (taking cetirizine for allergy)
Rescue medication: Albuterol inhaler - used about 4-5 times a day - takes prior to AM/PM Symbicort as
recommended, and then a couple of times during the day
Most recent patient self-reported data (MyChart smartphone monitoring) shows:

Time
Did you have ANY
SYMPTOMS of
asthma in the
past 24 hours?
What was your

4/16/2019
6:00 AM
I had SOME
asthma
symptoms
358

4/15/2019
7:01 AM
I had SOME
asthma
symptoms
357

4/14/2019
9:22 AM
I had SOME
asthma
symptoms
352

4/5/2019
7:52 AM
I had SOME
asthma
symptoms
401

4/3/2019
5:44 AM
I had SOME
asthma
symptoms
318

4/1/2019
2:23 PM
I had SOME
asthma
symptoms
533
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PEAK FLOW
today?
OBJECTIVE
Appears well - Normal effort with respiration
Peak flow today via digital PEF meter is 481 L/min, which is 100% of personal best (481)
FEV1 (today): 3.35 FEV1 Predicted: 4.15
• FEV1 % of predicted: 81
• FEV1 or PFM Zone: Green
ASSESSMENT
No current safety concerns: Symptoms have decreased over all, but noticing regular chest discomfort - needs to
follow up in office ASAP and may need stepwise increase to bring symptoms under control faster. Should follow
up ASAP for chest pain.
EPR-3 calculated asthma assessment:
Asthma control: Very poorly controlled
Asthma severity (EPR3): Severe persistent asthma
Guideline based assessment of controller therapy: Insufficient control medication
• Guideline recommended stepwise therapy: Step 5
• Provider prescribed stepwise therapy level: 4
• Patient using stepwise therapy level: 4
• Recommended ICS adjustments: Taking maximum dose prescribed by provider
• Recommended follow up: Follow up with PCP ASAP
Based on DHHS. National Heart Lung & Blood Institute. Asthma Care Quick Reference: Diagnosing and
Managing Asthma
PLAN
Asthma Education covered this visit:
What is asthma + what causes symptoms
What happens when asthma is uncontrolled
Demonstrates understanding
How do you know if your asthma is controlled?
Demonstrates understanding
Control vs. rescue medications
Demonstrates understanding
Recognizing symptoms of asthma
Demonstrates understanding
What to do during an asthma attack
Demonstrates understanding
Life threatening asthma symptoms
Demonstrates understanding
How to take inhalers correctly
Demonstrates understanding
How and why you should use a spacer
Demonstrates understanding
How to use a peak flow meter
Demonstrates understanding
Asthma triggers and how to handle them
Demonstrates understanding
Managing exercise induced asthma
Demonstrates understanding
Keeping track of symptoms
Using an asthma action plan
Personal goals for asthma management: Wants to get rid of chest discomfort; Total minutes asthma education: 35
Follow up plan: Schedule office visit with PCP ASAP, Follow up virtual visit in 2 weeks. Reinforced need to follow
up in office ASAP; given # to call clinic since he did not have it.

